Skip to main content
INNV
NASDAQ Life Sciences

InnovAge Raises Full-Year Guidance on Strong Q3 Revenue Growth, Adjusted EBITDA

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$8.3
Mkt Cap
$1.08B
52W Low
$2.84
52W High
$10.69
Market data snapshot near publication time

summarizeSummary

InnovAge Holding Corp. announced its fiscal third-quarter results, reporting a 15.5% increase in total revenues to $251.9 million and a significant rise in Adjusted EBITDA to $30.5 million. Despite these operational improvements, the company posted a net loss of $29.9 million, a notable increase from the prior year's $11.1 million loss, which contrasts with the 'significant return to profitability' reported in the previous fiscal second quarter. However, management expressed confidence, citing continued operational execution and platform investments. Crucially, InnovAge raised its full-year fiscal 2026 revenue and Adjusted EBITDA guidance, signaling a positive outlook for future performance. Traders will focus on the updated guidance and strong Adjusted EBITDA growth as key indicators, despite the GAAP net loss.

At the time of this announcement, INNV was trading at $8.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.84 to $10.69. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


show_chartPrice Chart

Share this article

Copied!

feed INNV - Latest Insights

INNV
May 07, 2026, 7:33 PM EDT
Filing Type: 10-Q
Importance Score:
8
INNV
May 05, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
INNV
May 05, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
INNV
Feb 03, 2026, 5:09 PM EST
Filing Type: 10-Q
Importance Score:
7
INNV
Feb 03, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
8